CIK 0001832038 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 53.4 M | 0 | |
| Net income (USD) | -52.5 M | -198.6 M | -241.3 M |
| Diluted EPS (USD/shares) | -0.3 | -1.81 | -2.23 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-29 | 8-K | 8-K items 8.01,9.01 | 2026-09-29 |
| 2026-09-02 | 4 | 4 | 2026-08-31 |
| 2026-09-02 | 3 | 3 | 2026-08-30 |
| 2026-09-01 | 4 | 4 | 2026-08-30 |
| 2026-09-01 | 8-K | 8-K items 5.02,8.01,9.01 | 2026-08-30 |
| 2026-08-18 | 4 | 4 | 2026-08-15 |
| 2026-08-18 | 4 | 4 | 2026-08-15 |
| 2026-08-18 | 4 | 4 | 2026-08-15 |
| 2026-08-18 | 4 | 4 | 2026-08-15 |
| 2026-08-18 | 4 | 4 | 2026-08-15 |
| 2026-08-17 | 144 | 144 | |
| 2026-08-17 | 144 | 144 | |
| 2026-08-17 | 144 | 144 | |
| 2026-08-17 | 144 | 144 | |
| 2026-08-17 | 144 | 144 | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-13 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-13 | 8-K | 8-K items 2.02,9.01 | 2026-08-13 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-08-04 | 3 | 3 | 2026-07-31 |
| 2026-07-28 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-24 | 8-K | 8-K items 3.01 | 2026-07-23 |
| 2026-07-06 | 8-K | 8-K items 8.01,9.01 | 2026-07-06 |
| 2026-05-21 | 4 | 4 | 2026-05-19 |
Forms on file (last 1,000): 4 122, 8-K 100, 3 40, 144 22, 10-Q 16, SC 13D/A 16, SCHEDULE 13G/A 15, CORRESP 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=IVVD (0.002 USD), /gw/filings/filings?ticker=IVVD&form=8-K, /gw/filings/facts?ticker=IVVD&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange